Simplex Trading
CRNX icon

Simplex Trading’s Crinetics Pharmaceuticals CRNX Stock Holding History

Simplex Trading’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$396K Buy
+10,900
New +$487K ﹤0.01% 3545
2025
Q4 		– Sell
-4,000
Closed -$166K – 8788
2025
Q3 		$166K Buy
4,000
+3,800
+1,900% +$122K ﹤0.01% 5155
2025
Q2 		$5K Sell
200
-200
-50% -$6.18K ﹤0.01% 7717
2025
Q1 		$13K Sell
400
-700
-64% -$26.1K ﹤0.01% 6891
2024
Q4 		$56K Buy
1,100
+600
+120% +$33.6K ﹤0.01% 5756
2024
Q3 		$25K Buy
500
+300
+150% +$15.5K ﹤0.01% 6489
2024
Q2 		$8K Sell
200
-11,100
-98% -$513K ﹤0.01% 7560
2024
Q1 		$528K Buy
11,300
+5,600
+98% +$219K ﹤0.01% 3808
2023
Q4 		$202K Sell
5,700
-112,000
-95% -$3.43M ﹤0.01% 4676
2023
Q3 		$3.5M Buy
117,700
+114,000
+3,081% +$2.35M ﹤0.01% 1594
2023
Q2 		$66K Buy
+3,700
New +$73.8K ﹤0.01% 5537
2022
Q3 		– Sell
-300
Closed -$5K – 10030
2022
Q2 		$5K Hold
300
– – ﹤0.01% 8805
2022
Q1 		$6K Buy
+300
New +$6.07K ﹤0.01% 9267

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Simplex Trading's CRNX Position: Q1 2026 in Review

Simplex Trading opened a new position in Crinetics Pharmaceuticals (CRNX) in Q1 2026: 108 shares worth $3.92K. The stake represents ﹤0.01% of the portfolio and ranks #8040 among its holdings. This is a return to the name: Simplex Trading previously reported a position in CRNX as recently as Q3 2025.

Simplex Trading first reported a position in CRNX in Q4 2021 and has held it in 11 quarters since. The position peaked at $3.28M in Q3 2023. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Simplex Trading held 108 shares of Crinetics Pharmaceuticals worth $3.92K as of Q1 2026.
  • Crinetics Pharmaceuticals was a new Simplex Trading position in Q1 2026.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #8040 holding.
  • Simplex Trading first reported a position in Crinetics Pharmaceuticals in Q4 2021 and has held it in 11 quarters since.
  • Simplex Trading's Crinetics Pharmaceuticals position peaked at $3.28M in Q3 2023.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.